Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Mereo BioPharma Group plc

Get SEC filing alerts via email and in your feed for Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

About Mereo BioPharma Group plc

Mereo BioPharma Group plc is a biopharmaceutical company specializing in developing innovative therapies for rare diseases. Its core focus includes late-stage clinical candidates like setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency-related lung disease. The company leverages strategic acquisitions, partnerships, and licensing to advance targeted treatments, primarily serving patients with high unmet medical needs in specialized markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Mereo BioPharma Group plc

1
1
Mereo BioPharma Group plc Mereo BioPharma Reports $6.7 Million Net Loss in Q1 2026, Improved from Previous Year

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Mereo BioPharma Group plc Mereo BioPharma Group Reports $0.5M Revenue and $41.9M Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Mereo BioPharma Group plc Mereo BioPharma Reports $7M Net Loss in Q3 2025, Revenue of $500K for Nine Months

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Mereo BioPharma Group plc Mereo BioPharma Reports $500,000 Revenue in Q2 2025, Net Loss Increases to $14.6 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Mereo BioPharma Group plc Mereo BioPharma Reports $12.9 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Mereo BioPharma Group plc Mereo BioPharma Reports $43.3 Million Net Loss for 2024, Revenue Declines to Nil

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Mereo BioPharma Group plc Mereo BioPharma Reports Net Loss of $15M, Increased Operating Expenses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments